Ligand Pharmaceuticals Incorporated (LGND)
| Market Cap | 6.18B +52.6% |
| Revenue (ttm) | 253.83M +1.0% |
| Net Income | 51.46M +5.9% |
| EPS | 2.39 -4.0% |
| Shares Out | 20.00M |
| PE Ratio | 129.12 |
| Forward PE | 44.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 135,759 |
| Open | 313.98 |
| Previous Close | 316.27 |
| Day's Range | 308.59 - 314.79 |
| 52-Week Range | 175.89 - 326.63 |
| Beta | 1.04 |
| Analysts | Strong Buy |
| Price Target | 361.27 (+17.0%) |
| Earnings Date | Oct 29, 2026 |
About LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteopor... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for LGND stock is "Strong Buy." The 12-month stock price target is $361.27, which is an increase of 17.00% from the latest price.
News
Ligand price target raised to $350 from $345 at Barclays
Barclays analyst Glen Santangelo raised the firm’s price target on Ligand (LGND) to $350 from $345 and keeps an Overweight rating on the shares. The share setup post the Q3…
Ligand price target raised to $402 from $397 at Citi
Citi analyst Yigal Nochomovitz raised the firm’s price target on Ligand (LGND) to $402 from $397 and keeps a Buy rating on the shares.
Ligand price target raised to $346 from $334 at Oppenheimer
Oppenheimer raised the firm’s price target on Ligand (LGND) to $346 from $334 and keeps an Outperform rating on the shares. The firm notes the company’s Q3 royalty revenue grew…
Ligand price target raised to $350 from $332 at Stifel
Stifel analyst Annabel Samimy raised the firm’s price target on Ligand (LGND) to $350 from $332 and keeps a Buy rating on the shares.
Ligand Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 royalty revenue grew 51% YoY, and adjusted EPS guidance rose to $9.50-$9.75. The expanded portfolio includes more than 200 royalty assets, with up to seven pivotal readouts expected through 2027.
Ligand Pharmaceuticals Earnings release: Q3 2026
Ligand Pharmaceuticals released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Ligand Pharmaceuticals Slides: Q3 2026
Ligand Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Ligand Pharmaceuticals Quarterly report: Q3 2026
Ligand Pharmaceuticals has published its Q3 2026 quarterly earnings report on October 29, 2026.
Ligand reports Q3 EPS $2.67, consensus $2.33
“Ligand (LGND) delivered another strong quarter, with royalty revenue growing 51% year-over-year, driven by contribution from the XOMA portfolio and continued commercial momentum across our key royalt...
Ligand Reports Third Quarter 2026 Financial Results
Third-quarter royalty revenue up 51% year-over-year to $70.3 million Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.50 1 ; Reaffirms Revenue Guidance Conferen...
Ligand to Participate in November Investor Conferences
JUPITER, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor ...
Ligand to Host Investor Day on December 8, 2026
JUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from 10:30...
Ligand price target raised to $406 from $388 at BofA
BofA raised the firm’s price target on Ligand (LGND) to $406 from $388 and keeps a Buy rating on the shares. The firm updated estimates ahead of Q3 earnings reports…
Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026
JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29, 20...
Ligand initiated with an Overweight at Barclays
Barclays analyst Glen Santangelo initiated coverage of Ligand (LGND) with an Overweight rating and $345 price target The firm says Ligand is “differentiated” with a focus on aggregating biopharma roya...
Wainwright sees upside in Ligand after new CAR-T investment in AvenCell
H.C. Wainwright analyst Joseph Pantginis notes that this morning, Ligand (LGND) announced an up to $47M investment into AvenCell Therapeutics for development of its potentially differentiated CAR-T as...
Ligand enters financing agreement with AvenCell for up to $47M
Ligand (LGND) Pharmaceuticals announced that it has entered into a financing agreement with AvenCell Therapeutics for up to $47M. The investment will help advance AvenCell’s pipeline, including AVC-20...
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a ...
Ligand price target raised to $397 from $390 at Citi
Citi raised the firm’s price target on Ligand (LGND) to $397 from $390 and keeps a Buy rating on the shares. The firm cites the company’s acquisition of a royalty…
Ligand enters royalty agreement with Sydnexis for Ryjunea
Sydnexis announced an agreement with Ligand (LGND) Pharmaceuticals to sell its royalty rights associated with net sales of Ryjunea in Europe, the Middle East, and Africa. Under the terms of…
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced a...
Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new...
Ligand acquires royalty, milestone interest in Santen’s Ryjunea from Sydnexis
Ligand (LGND) Pharmaceuticals announced it has acquired an ascending tiered royalty interest in Santen Pharmaceutical’s Ryjunea from Sydnexis for a $23M upfront payment. Under the terms of the agreeme...
Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea® from Sydnexis for $23 Million
Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to ...
Ligand Pharmaceuticals Transcript: 17th Annual Midwest IDEAS Conference
The company has rapidly scaled its royalty aggregation strategy, highlighted by the XOMA acquisition, which doubled its portfolio and is immediately accretive. Strong financials, a robust pipeline, and disciplined investment processes position it for significant near- and long-term growth.